204 related articles for article (PubMed ID: 37132085)
1. Who responds to a multi-component treatment for cannabis use disorder? Using multivariable and machine learning models to classify treatment responders and non-responders.
Tomko RL; Wolf BJ; McClure EA; Carpenter MJ; Magruder KM; Squeglia LM; Gray KM
Addiction; 2023 Oct; 118(10):1965-1974. PubMed ID: 37132085
[TBL] [Abstract][Full Text] [Related]
2. Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder.
Tomko RL; Baker NL; Hood CO; Gilmore AK; McClure EA; Squeglia LM; McRae-Clark AL; Sonne SC; Gray KM
Psychopharmacology (Berl); 2020 Feb; 237(2):479-490. PubMed ID: 31712969
[TBL] [Abstract][Full Text] [Related]
3. A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults.
Gray KM; Sonne SC; McClure EA; Ghitza UE; Matthews AG; McRae-Clark AL; Carroll KM; Potter JS; Wiest K; Mooney LJ; Hasson A; Walsh SL; Lofwall MR; Babalonis S; Lindblad RW; Sparenborg S; Wahle A; King JS; Baker NL; Tomko RL; Haynes LF; Vandrey RG; Levin FR
Drug Alcohol Depend; 2017 Aug; 177():249-257. PubMed ID: 28623823
[TBL] [Abstract][Full Text] [Related]
4. A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol.
Bhardwaj AK; Mills L; Doyle M; Sahid A; Montebello M; Monds L; Arunogiri S; Haber P; Lorenzetti V; Lubman DI; Malouf P; Harrod ME; Dunlop A; Freeman T; Lintzeris N
BMC Psychiatry; 2024 Mar; 24(1):175. PubMed ID: 38433233
[TBL] [Abstract][Full Text] [Related]
5. Gender differences among treatment-seeking adults with cannabis use disorder: Clinical profiles of women and men enrolled in the achieving cannabis cessation-evaluating N-acetylcysteine treatment (ACCENT) study.
Sherman BJ; McRae-Clark AL; Baker NL; Sonne SC; Killeen TK; Cloud K; Gray KM
Am J Addict; 2017 Mar; 26(2):136-144. PubMed ID: 28152236
[TBL] [Abstract][Full Text] [Related]
6. The effect of N-acetylcysteine on alcohol use during a cannabis cessation trial.
Squeglia LM; Tomko RL; Baker NL; McClure EA; Book GA; Gray KM
Drug Alcohol Depend; 2018 Apr; 185():17-22. PubMed ID: 29413434
[TBL] [Abstract][Full Text] [Related]
7. The role of depressive symptoms in treatment of adolescent cannabis use disorder with N-Acetylcysteine.
Tomko RL; Gilmore AK; Gray KM
Addict Behav; 2018 Oct; 85():26-30. PubMed ID: 29803870
[TBL] [Abstract][Full Text] [Related]
8. Achieving cannabis cessation -- evaluating N-acetylcysteine treatment (ACCENT): design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network.
McClure EA; Sonne SC; Winhusen T; Carroll KM; Ghitza UE; McRae-Clark AL; Matthews AG; Sharma G; Van Veldhuisen P; Vandrey RG; Levin FR; Weiss RD; Lindblad R; Allen C; Mooney LJ; Haynes L; Brigham GS; Sparenborg S; Hasson AL; Gray KM
Contemp Clin Trials; 2014 Nov; 39(2):211-23. PubMed ID: 25179587
[TBL] [Abstract][Full Text] [Related]
9. Correlates of cannabis use disorder in the United States: A comparison of logistic regression, classification trees, and random forests.
Dell NA; Vaughn MG; Prasad Srivastava S; Alsolami A; Salas-Wright CP
J Psychiatr Res; 2022 Jul; 151():590-597. PubMed ID: 35636037
[TBL] [Abstract][Full Text] [Related]
10. Psychosocial interventions for cannabis use disorder.
Gates PJ; Sabioni P; Copeland J; Le Foll B; Gowing L
Cochrane Database Syst Rev; 2016 May; 2016(5):CD005336. PubMed ID: 27149547
[TBL] [Abstract][Full Text] [Related]
11. [Cannabis cessation interventions offered to young French users: predictors of follow-up].
Abdoul H; Le Faou AL; Bouchez J; Touzeau D; Lagrue G
Encephale; 2012 Apr; 38(2):141-8. PubMed ID: 22516272
[TBL] [Abstract][Full Text] [Related]
12. Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol.
Bhardwaj AK; Allsop DJ; Copeland J; McGregor IS; Dunlop A; Shanahan M; Bruno R; Phung N; Montebello M; Sadler C; Gugusheff J; Jackson M; Luksza J; Lintzeris N;
BMC Psychiatry; 2018 May; 18(1):140. PubMed ID: 29776349
[TBL] [Abstract][Full Text] [Related]
13. Cross-domain correlates of cannabis use disorder severity among young adults.
Schuster RM; Hareli M; Moser AD; Lowman K; Gilman J; Ulysse C; Schoenfeld D; Evins AE
Addict Behav; 2019 Jun; 93():212-218. PubMed ID: 30753972
[TBL] [Abstract][Full Text] [Related]
14. Construct validity of DSM-5 cannabis use disorder diagnosis and severity levels in adults with problematic substance use.
Fink DS; Shmulewitz D; Mannes ZL; Stohl M; Livne O; Wall M; Hasin DS
J Psychiatr Res; 2022 Nov; 155():387-394. PubMed ID: 36182768
[TBL] [Abstract][Full Text] [Related]
15. Tobacco use during cannabis cessation: Use patterns and impact on abstinence in a National Drug Abuse Treatment Clinical Trials Network study.
McClure EA; Baker NL; Sonne SC; Ghitza UE; Tomko RL; Montgomery L; Babalonis S; Terry GE; Gray KM
Drug Alcohol Depend; 2018 Nov; 192():59-66. PubMed ID: 30218864
[TBL] [Abstract][Full Text] [Related]
16. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents.
Gray KM; Carpenter MJ; Baker NL; DeSantis SM; Kryway E; Hartwell KJ; McRae-Clark AL; Brady KT
Am J Psychiatry; 2012 Aug; 169(8):805-12. PubMed ID: 22706327
[TBL] [Abstract][Full Text] [Related]
17. Medical conditions of primary care patients with documented cannabis use and cannabis use disorder in electronic health records: a case control study from an academic health system in a medical marijuana state.
Padwa H; Huang D; Mooney L; Grella CE; Urada D; Bell DS; Bass B; Boustead AE
Subst Abuse Treat Prev Policy; 2022 May; 17(1):36. PubMed ID: 35527269
[TBL] [Abstract][Full Text] [Related]
18. Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder.
Mills L; Dunlop A; Montebello M; Copeland J; Bruno R; Jefferies M; Mcgregor I; Lintzeris N
Subst Abuse Treat Prev Policy; 2022 Oct; 17(1):67. PubMed ID: 36209081
[TBL] [Abstract][Full Text] [Related]
19. Pharmacotherapies for cannabis dependence.
Nielsen S; Gowing L; Sabioni P; Le Foll B
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD008940. PubMed ID: 30687936
[TBL] [Abstract][Full Text] [Related]
20. Association of Comorbid Behavioral and Medical Conditions With Cannabis Use Disorder in Pregnancy.
Meinhofer A; Hinde JM; Keyes KM; Lugo-Candelas C
JAMA Psychiatry; 2022 Jan; 79(1):50-58. PubMed ID: 34730782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
